Showing results (151-160 of 773) with videos related to
Sort By:
Pageof 78
Medical Care|August 4, 2009
An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomesWilliam H Shrank, Amanda Patrick, Patrick P Gleason, et al.Journal of Clinical Epidemiology|July 11, 2006
Selective prescribing led to overestimation of the benefits of lipid-lowering drugsRobert J Glynn, Sebastian Schneeweiss, Philip S Wang, et al.The Patient|September 23, 2018
General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice ExperimentMehdi Najafzadeh, Sebastian Schneeweiss, Niteesh K Choudhry, et al.Annals of Internal Medicine|August 21, 2023
The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited EvidenceLiam Bendicksen, Diana M Zuckerman, Jerry Avorn, et al.The American Journal of Managed Care|December 4, 2015
Medication adherence and healthcare disparities: impact of statin co-payment reductionJennifer Lewey, William H Shrank, Jerry Avorn, et al.Journal of General Internal Medicine|February 17, 2018
Application and impact of run-in studiesMichael Fralick, Jerry Avorn, Jessica M Franklin, et al.JAMA Oncology|April 4, 2024
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer TherapiesAriadna Tibau, Thomas J Hwang, Consolacion Molto, et al.Journal of General Internal Medicine|November 16, 2006
Angiotensin inhibition after myocardial infarction: does drug class matter?Wolfgang C Winkelmayer, Michael A Fischer, Sebastian Schneeweiss, et al.The American Journal of Cardiology|June 12, 2010
Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery diseaseAlexander Kulik, Jagmeet P Singh, Raisa Levin, et al.Journal of Clinical Epidemiology|January 7, 2011
A combined comorbidity score predicted mortality in elderly patients better than existing scoresJoshua J Gagne, Robert J Glynn, Jerry Avorn, et al.Pageof 78